Lilly Asia Ventures led the Sinopharm-backed oncology, immunity and inflammation therapeutics startup’s series B round, which included Legend Capital.

McKesson Ventures and Medidata Solutions participated in a round that will help the medical data provider in the fight against rare diseases.

Legend Capital took part in a $46.3m series B-plus round for enzyme product developer Yeasen Biotechnology two months after the latter closed its series B round.

Ferrovial and Mitsui Fudosan helped mobility platform developer Maas Global hike its latest round to nearly $46m while automotive technology developer Visic Technologies raised $35m.

The $3bn merger of meditation app developer Headspace and digital mental health services provider Ginger would present a new path for a plethora of corporate investors.

Optum has signed on to the fight against obesity, backing the telemedicine programme provider and taking its overall funding to over $127m.

M12 helped cybersecurity software producer Hunters raise $30m while Scor and Transamerica are set to exit patient monitoring software developer 100Plus.

Bristol Myers Squibb returned to reinvest in the cardiac disease therapy developer having backed its 2017 series A round with Boehringer Ingelheim.

The series C1 round pushed the Sanofi and Alexandria Real Estate Equities-backed oral therapeutics developer’s total funding to about $200m.

Immunotherapy developer Elixiron has closed its series A1 round with capital from investors including Hong Tai Electric Industrial.